US20200129648A1 - Sterilization of Medical Dressings with Enhanced Antimicrobial Properties - Google Patents
Sterilization of Medical Dressings with Enhanced Antimicrobial Properties Download PDFInfo
- Publication number
- US20200129648A1 US20200129648A1 US16/602,440 US201916602440A US2020129648A1 US 20200129648 A1 US20200129648 A1 US 20200129648A1 US 201916602440 A US201916602440 A US 201916602440A US 2020129648 A1 US2020129648 A1 US 2020129648A1
- Authority
- US
- United States
- Prior art keywords
- sponge
- dressing
- dyes
- polymer
- sterile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 24
- 230000001954 sterilising effect Effects 0.000 title claims description 50
- 238000004659 sterilization and disinfection Methods 0.000 title claims description 47
- 239000000975 dye Substances 0.000 claims abstract description 42
- 206010052428 Wound Diseases 0.000 claims abstract description 31
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 31
- 230000005855 radiation Effects 0.000 claims abstract description 25
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000011148 porous material Substances 0.000 claims abstract description 10
- 239000002993 sponge (artificial) Substances 0.000 claims abstract description 7
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000853 adhesive Substances 0.000 claims abstract description 6
- 230000001070 adhesive effect Effects 0.000 claims abstract description 6
- 239000002563 ionic surfactant Substances 0.000 claims abstract description 6
- 239000010703 silicon Substances 0.000 claims abstract description 6
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 6
- 239000002738 chelating agent Substances 0.000 claims abstract description 5
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 5
- 239000003638 chemical reducing agent Substances 0.000 claims abstract 4
- 239000004814 polyurethane Substances 0.000 claims description 37
- 229920000642 polymer Polymers 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 30
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims description 12
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 12
- 229920002554 vinyl polymer Polymers 0.000 claims description 9
- 229920002635 polyurethane Polymers 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- -1 and TrypLE) Proteins 0.000 claims description 7
- 239000013078 crystal Substances 0.000 claims description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 5
- 150000001241 acetals Chemical class 0.000 claims description 5
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 102000013142 Amylases Human genes 0.000 claims description 3
- 108010065511 Amylases Proteins 0.000 claims description 3
- 108010059892 Cellulase Proteins 0.000 claims description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 3
- 108010088842 Fibrinolysin Proteins 0.000 claims description 3
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims description 3
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 102400000830 Saposin-B Human genes 0.000 claims description 3
- 101800001697 Saposin-B Proteins 0.000 claims description 3
- 108010023197 Streptokinase Proteins 0.000 claims description 3
- 229940106157 cellulase Drugs 0.000 claims description 3
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 3
- 239000003527 fibrinolytic agent Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 150000002739 metals Chemical class 0.000 claims description 3
- 108010020132 microbial serine proteinases Proteins 0.000 claims description 3
- 229940086319 nattokinase Drugs 0.000 claims description 3
- 108010073682 nattokinase Proteins 0.000 claims description 3
- 150000003009 phosphonic acids Chemical class 0.000 claims description 3
- 229940012957 plasmin Drugs 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 229960005202 streptokinase Drugs 0.000 claims description 3
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 claims description 2
- ALJHHTHBYJROOG-UHFFFAOYSA-N 7-(dimethylamino)phenothiazin-3-one Chemical compound C1=CC(=O)C=C2SC3=CC(N(C)C)=CC=C3N=C21 ALJHHTHBYJROOG-UHFFFAOYSA-N 0.000 claims description 2
- DDGMDTGNGDOUPX-UHFFFAOYSA-N 7-methyliminophenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[NH+]C)C=CC3=NC2=C1 DDGMDTGNGDOUPX-UHFFFAOYSA-N 0.000 claims description 2
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 claims description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 108010076830 Thionins Proteins 0.000 claims description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 claims description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 claims description 2
- BGLGAKMTYHWWKW-UHFFFAOYSA-N acridine yellow Chemical compound [H+].[Cl-].CC1=C(N)C=C2N=C(C=C(C(C)=C3)N)C3=CC2=C1 BGLGAKMTYHWWKW-UHFFFAOYSA-N 0.000 claims description 2
- 125000005210 alkyl ammonium group Chemical group 0.000 claims description 2
- 125000005599 alkyl carboxylate group Chemical group 0.000 claims description 2
- 150000008051 alkyl sulfates Chemical class 0.000 claims description 2
- PGWTYMLATMNCCZ-UHFFFAOYSA-M azure A Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 PGWTYMLATMNCCZ-UHFFFAOYSA-M 0.000 claims description 2
- KFZNPGQYVZZSNV-UHFFFAOYSA-M azure B Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(NC)=CC=C3N=C21 KFZNPGQYVZZSNV-UHFFFAOYSA-M 0.000 claims description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001506 brilliant green Drugs 0.000 claims description 2
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 claims description 2
- 229960000800 cetrimonium bromide Drugs 0.000 claims description 2
- 229960002788 cetrimonium chloride Drugs 0.000 claims description 2
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 2
- 229930003836 cresol Natural products 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- DXQWPBNWAKTXPF-UHFFFAOYSA-M hexadecyl(trimethyl)azanium;octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC[N+](C)(C)C DXQWPBNWAKTXPF-UHFFFAOYSA-M 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 229960000901 mepacrine Drugs 0.000 claims description 2
- YYGBVRCTHASBKD-UHFFFAOYSA-M methylene green Chemical compound [Cl-].C1=CC(N(C)C)=C([N+]([O-])=O)C2=[S+]C3=CC(N(C)C)=CC=C3N=C21 YYGBVRCTHASBKD-UHFFFAOYSA-M 0.000 claims description 2
- RBDJQFKUZPMOFH-UHFFFAOYSA-I pentasodium;3-amino-4-[[4-[4-[(2-amino-3,6-disulfonatonaphthalen-1-yl)diazenyl]-3-sulfonatophenyl]phenyl]diazenyl]naphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(N)=C1N=NC1=CC=C(C=2C=C(C(N=NC=3C4=CC=C(C=C4C=C(C=3N)S([O-])(=O)=O)S([O-])(=O)=O)=CC=2)S([O-])(=O)=O)C=C1 RBDJQFKUZPMOFH-UHFFFAOYSA-I 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 238000002459 porosimetry Methods 0.000 claims description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 2
- 229950003937 tolonium Drugs 0.000 claims description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 claims description 2
- 241001071795 Gentiana Species 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000006260 foam Substances 0.000 description 12
- 239000004372 Polyvinyl alcohol Substances 0.000 description 10
- 229920002451 polyvinyl alcohol Polymers 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 230000009467 reduction Effects 0.000 description 7
- 239000013464 silicone adhesive Substances 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229920005830 Polyurethane Foam Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 229920002529 medical grade silicone Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229920002118 antimicrobial polymer Polymers 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229920006268 silicone film Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/0035—Gamma radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00059—Accessories for dressings provided with visual effects, e.g. printed or colored
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
- A61F13/01017—Non-adhesive bandages or dressings characterised by the material synthetic, e.g. polymer based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01021—Non-adhesive bandages or dressings characterised by the structure of the dressing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0094—Gaseous substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/081—Gamma radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/20—Gaseous substances, e.g. vapours
- A61L2/206—Ethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00314—Wound bandages with surface treatments
- A61F2013/00336—Wound bandages with surface treatments polymeric resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/42—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators with wetness indicator or alarm
- A61F2013/429—Thermochromic materials, e.g. ink or dye
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
- A61F2013/530481—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having superabsorbent materials, i.e. highly absorbent polymer gel materials
- A61F2013/530583—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having superabsorbent materials, i.e. highly absorbent polymer gel materials characterized by the form
- A61F2013/530649—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having superabsorbent materials, i.e. highly absorbent polymer gel materials characterized by the form in sponge or foam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- the present dressing relates to a method of sterilization of medical devices and more particularly, medical dressings. More particularly, the present invention relates to sterilization with gamma radiation and ethylene oxide of foamed polymers containing antimicrobial positive and negative dyes and coated with a silicone adhesive.
- sterilization refers to the elimination of microorganisms such as fungi, bacteria and viruses, or a reduction in the bioburden of an item where bioburden refers to the number of micro-organisms with which the item is contaminated.
- the degree of sterilization is typically measured by a sterility assurance level (SAL) which refers to the probability of a viable microorganism being present on a product unit after sterilization.
- SAL sterility assurance level
- sterilization procedures There are a number of sterilization procedures.
- the broad categories of sterilization include heat, chemicals, and irradiation.
- An example of using heat to sterilize is autoclaving of medical instruments.
- Cooking or canning food is also another application of using heat for sterilization.
- a number of chemicals can be used for sterilization including ozone, chlorine dioxide, ethylene oxide, and hydrogen peroxide.
- Irradiation includes exposure to gamma rays, x-rays, or an electron beam.
- the present invention is directed to methods of sterilization that limit or eliminate some of these negative impacts of sterilization on the effectiveness of device, and particularly methods involving ethylene oxide sterilization.
- Ethylene oxide (EO, EtO) sterilization is a broadly used terminal sterilization method for medical devices.
- EO sterilization and irradiation as a terminal sterilization can also cause limitations for medical devices or more specifically wound dressings containing antimicrobial positive and negative dyes.
- One example is a limitation on materials that can be used as different materials have their properties changed by sterilization.
- medical silicone adhesives and silicon rubbers are excluded from use in gamma terminally sterile products, e.g. as cover dressings, despite their excellent clinical performance. Therefore, a wound dressing comprised of an antimicrobial positive and negative dyed wound dressing and a silicone adhesive is not known in the prior art.
- Polymeric based wound dressings made from e.g. polyvinyl alcohol (PVA) or polyurethane-polyether (PU) polymers and that contain antimicrobial positive and negative dyes are terminally sterilized using irradiation, e.g. Hydrofera® Blue (Hydrofera, LLC), RTD® Wound Dressing (Keneric Healthcare), NovaGranTM Blue Plus DressingTM (Principle Business Enterprises, Inc.).
- irradiation e.g. Hydrofera® Blue (Hydrofera, LLC), RTD® Wound Dressing (Keneric Healthcare), NovaGranTM Blue Plus DressingTM (Principle Business Enterprises, Inc.
- Wounds often have multiple barriers to healing. Wound healing and infection is influenced by the relationship between the ability of bacteria to create a stable, mature community within a wound environment and the ability of the host to control the bacterial community. Since bacteria are rapidly able to form their own protective microenvironment (biofilm) following their attachment to a surface, the ability of the host to control these organisms is likely to decrease as the biofilm community matures. Within a stable biofilm community, interactions between aerobic and anaerobic bacteria are likely to increase their net pathogenic effect, enhancing their potential to cause infection and delay healing. Over the last few years, some have linked biofilm to chronic wounds. Microscopic evaluation or chronic wounds showed well organized biofilm with extracellular polymeric substance adhered around colony bacteria in at least 60% of the chronic wounds.
- the present invention describes Ethylene Oxide terminally sterilizing sterile dressings with enhanced antimicrobial properties.
- Enhanced antimicrobial properties are achieved through the method of using gamma irradiation as a processing step on the dyed medical device prior to final assembly and terminal EO sterilization.
- the invention allows for incorporation of non-gamma stable parts, e.g. silicones, in the final assembled product followed by terminal EO sterilization of the finished device.
- the gamma irradiation process step prior to the terminal EO sterilization surprisingly gives improved antimicrobial properties in comparison to the same device without the prior irradiative step.
- the device is an antibacterial dressing.
- the invention is directed to methods and processes for making these terminal EO sterile antimicrobial positive and negative dyed medical devices.
- FIG. 1 is a schematic block drawing of gamma radiation with subsequent EO sterilization
- FIG. 2 is a schematic block drawing of gamma radiation with two comparative EO sterilization methods
- FIG. 3 is a schematic block drawing like FIG. 2 with EO sterilization before the gamma sterilization step
- FIG. 4 is a plan view of the inventive dressing showing the silicone sheet extending beyond the sponge material.
- any ranges presented are inclusive of the end-points.
- a temperature between 10° C. and 30° C.” or “a temperature from 10° C. to 30° C.” includes 10° C. and 30° C., as well as any temperature in between.
- words of approximation when used herein such as, without limitation, “about” “substantially,” “essentially” and “approximately” mean that the word or phrase modified by the term need not be exactly that which is written but may vary from that written description to some extent. The extent to which the description may vary will depend on how great a change can be instituted and have one of ordinary skill in the art recognize the modified version as still having the properties, characteristics and capabilities of the modified word or phrase.
- a numerical value herein that is modified by a word of approximation may vary from the stated value by plus or minus 15%, unless expressly stated otherwise.
- wound is to be understood in its broadest sense, i.e. as any exterior part of a human or animal body that may be in need of treatment, particularly antibacterial treatment.
- wounds in the present context includes but are not limited to: Any laceration to the skin, such as a wound, a chronic wound, a burn wound, a cut, wounds associated with dermatological conditions, grafts, pressure wounds, traumatic wounds, underlying infections with fistulation from bone, joint or soft tissue.
- the present invention uses polymeric foam or sponges treated with antibacterial or antimicrobial material which is placed over the wound.
- the wound dressing may be a foam or sponge material and may be polymeric in composition where the polymer can be a synthetic substance, a natural substance or combinations thereof.
- the synthetic polymer can be polyvinyl formal (PVF), polyvinyl acetal, polyurethane, polyester, polyethylene terephthalate or a mixture of polymers.
- the natural polymer material can be either animal or plant derived, for example, collagen, or chitosan.
- the preferred sponge material is polyvinyl acetal, polyurethane or polyvinyl formal.
- the foam or sponge has a morphology characterized by an average pore throat diameter of 0.5-500 ⁇ m, a fluid retention of 5.5-25.0 mL fluids/g porous material, a density of 0.05-0.15 g polymer/cm 3 porous material, and a porosity of 60-99.5%.
- the cell structure is characterized as open/interconnected with through pores that can be evaluated by techniques such as capillary flow porometry and liquid extrusion porosimetry.
- the silicon adhesive is attached to a silicone film sheet 30 and is applied to a planar surface 32 of the sponge material dressing 40.
- the film sheet may extend beyond the dressing where it can adhere to the skin surface and keep the dressing in place as is shown in FIG. 4 .
- While the preferred embodiment of the invention is directed toward treated sponge dressings, it is envisioned as being used on other medical devices such as polyurethane catheters which are highly prone to infection.
- the dyes are clinically safe and have antimicrobial properties.
- antimicrobial is defined as having the ability to destroy or inhibit the growth of microorganisms, and comprises one or more of the following: antibacterial, antifungal, antiprotozoal, and antiviral.
- the inventive sterile dressing for treating wounds is made from a polymer sponge containing a plurality of antimicrobial dyes with at least one dye being gram positive and at least one other dye being gram negative. The dressing is exposed to both gamma radiation and ethylene oxide, which increase the sterilibility and allow a silicon adhesive to be secured to said sponge surface.
- Dyes can include, for example, triaryl or diarylmethanes, methylene blue, toluidine blue, methylene violet, azure A, azure B, azure C, brilliant cresol blue, thionin, methylene green, bromcresol green, crystal violet, acridine orange, brilliant green, acridine yellow, quinacrine, trypan blue, trypan red and mixtures of these dyes.
- the dyes are methylene blue and crystal violet.
- the above dye listing contains gram positive and gram negative dyes. Dyes of both charges are utilized to combat a large family of bacteria having gram positive and gram negative characteristics.
- Other antimicrobials agents can include e.g. chlorhexidine, rifampicin, sparfloxacin and triclosan.
- the activation by irradiation occurs after terminal sterilization with EO.
- masking techniques may be used to shield the non-compatible parts of the sterile device from radiation exposure.
- radiation sources with spatial coherence e.g. lasers
- These radiation sources may also have high temporal coherence.
- Antibacterial activity is measured in the following manner.
- Staphylococcus aureus (SA, ATCC #6538), Escherichia coli (EC, ATCC #11775), and Pseudomonas aeruginosa (PA, ATCC #9027). These bacteria are three of the five most common bacteria found in wound infections with Staphylococcus aureus (SA, ATCC #6538) being the most common.
- PU foam, PVA foam and PVF foam were dyed with methylene blue (MB) and crystal violet (CV), washed with water and dried.
- the dyed foams or sponge dressings 10 were then processed through gamma irradiation 12 and EO 14 steps to obtain test units 18 in the order shown in FIG. 1 .
- the dyed foam material samples were measured for antibacterial properties using the method described in Example 1, with the data being shown in Table 1.
- Table 1 shows that gamma irradiation as a process step undertaken prior to EO sterilization gave better antibacterial activity than the EO sterilized only test samples.
- the Table 1 notation PU 1 in the Polymer column denotes an example using only one dye.
- PU foam was dyed with methylene blue (MB) and crystal violet (CV), washed with water and dried.
- the dyed foam 10 was then processed using gamma irradiation 12 per Example 2 followed by EO 14 as described in Example 2 or by standard EO sterilization 16 conditions to obtain test samples 18 as listed below.
- the processing order is outlined in FIG. 2 .
- PU foam was dyed with methylene blue (MB) and/or crystal violet (CV), washed with water and dried.
- the dyed foams 10 were then processed as noted in example 2 conditions with the EO 14 and/or gamma irradiative 12 steps in the order shown in FIG. 3 .
- the dyed foams were measured for antibacterial properties using the method described in Example 1, and the data is found in Table 3.
- Table 3 The data shows that gamma irradiation 12 as a process step after EO sterilization gave better antibacterial activity than the EU sterilized only samples.
- White PU foam was processed using gamma radiation at a dose of 25-36 kGy. The foam was then dyed as described in Example 2 or 3 and sterilized by EO as described in Example 2 and 3 and the data found in the tables.
- Radiation activated polymers are characterized by a proportionally larger population of mobile polymer segments vs. their EO only sterilized analogs. Said population of more mobile segments may be distinguished from those without using differential scanning colorimetry, where differences in glass transition temperature (T g ) profiles are measured.
- T g glass transition temperature
- the radiation activated polymers have one or more glass transition endotherms, and the EO only analogs have none detected.
- the radiation activated polymers show an increase of greater than 1° C. in the T g temperature in going from the 1st to 2 nd heat cycle vs the EO only analog which shows no change.
- a change in the population of mobile polymer segments may translate to a more therapeutically effective antibacterial agent release from the material.
- Dyed foam samples were processed through gamma irradiative and/or EO steps as described in Example 2. When both irradiation and EO steps were conducted, irradiation preceded EO.
- DSC Differential Scanning calorimetry
- Step 2 (° C.) Polymer Sample ID Gamma EO Gamma 1st Heat 2nd Heat 1 st to 2nd PVA 042519.4 X 67.01 1 1.40 3.37 PVA 042519.5 X X 66.88 6.20 2.22 PVA 042519.6 X ND ND ND PVA 062619.1 X X 62.45 2 56.97 5.48 PU 042519.7 X ⁇ 30.30 ⁇ 0.47 8.27 PU 042519.8 X X ⁇ 31.07 ⁇ 28.18 2.89 PU 042519.9 X ⁇ 31.81 ⁇ 31.81 0 PU 062619.2 X X ⁇ 29.30 ⁇ 19.99 9.31 1 A second minor endotherm observed on the first heat only at 48.56° C. 2 A second minor endotherm observed on the first heat only at 52.44°
- Biofilm reduction agents are clinically safe and help remove biofilm by breaking up the film structure. Such agents are incorporated onto the sponge prior to the sterilization steps.
- enzymes are used to target and break down the extracellular polymer substances of the biofilm and include amylase enzymes (e.g. amyloglucosidase, bacterial amylo novo), protease enzymes (e.g. savinase and everlase) fibrinolytic agents (e.g. plasmin, streptokinase, and nattokinase, and TrypLE), deoxyribonuclease I, glycoside hydrolase dispersin B, and cellulase.
- amylase enzymes e.g. amyloglucosidase, bacterial amylo novo
- protease enzymes e.g. savinase and everlase
- fibrinolytic agents e.g. plasmin, streptokinase, and nat
- chelating agents are used in the sponge body to sequester the metals that crosslink polysaccharides in the biofilm including ethylenediaminetetraacetic acid (EDTA), citrates, phosphonates and phosphonic acids.
- EDTA ethylenediaminetetraacetic acid
- citrates citrates
- phosphonates phosphonic acids
- Ionic surfactants are used to solubilize the biofilm macromolecules, including ionic and non-ionic surfactants.
- Ionic surfactants may be negatively charged, positively charged, or zwitterionic, and include alkyl sulfates (e.g. sodium dodecyl sulfate), alkyl carboxylates, (e.g. sodium stearate), tertiary or quarternary alkyl ammoniums (e.g. cetrimonium bromide, cetrimonium chloride, cetrimonium stearate), 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS).
- Non-ionic surfactants may include polyethylene glycol, polyethylene oxide, Triton, Tergitol, Pluronics, IGEPELS, Tweens, fatty acid esters.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
- This application claims priority and benefits from provisional patent application No. 62/741,839 filed Oct. 5, 2018.
- None
- None.
- The present dressing relates to a method of sterilization of medical devices and more particularly, medical dressings. More particularly, the present invention relates to sterilization with gamma radiation and ethylene oxide of foamed polymers containing antimicrobial positive and negative dyes and coated with a silicone adhesive.
- The term sterilization refers to the elimination of microorganisms such as fungi, bacteria and viruses, or a reduction in the bioburden of an item where bioburden refers to the number of micro-organisms with which the item is contaminated. The degree of sterilization is typically measured by a sterility assurance level (SAL) which refers to the probability of a viable microorganism being present on a product unit after sterilization.
- There are a number of sterilization procedures. The broad categories of sterilization include heat, chemicals, and irradiation. An example of using heat to sterilize is autoclaving of medical instruments. Cooking or canning food is also another application of using heat for sterilization. A number of chemicals can be used for sterilization including ozone, chlorine dioxide, ethylene oxide, and hydrogen peroxide. Irradiation includes exposure to gamma rays, x-rays, or an electron beam.
- Many medical devices undergo terminal sterilization; that is sterilization occurs in the final packaged product. Thus, the sterilization operation may have a negative impact on the material of the device, and/or any active biocidal agents contained in the device. The present invention is directed to methods of sterilization that limit or eliminate some of these negative impacts of sterilization on the effectiveness of device, and particularly methods involving ethylene oxide sterilization.
- Ethylene oxide (EO, EtO) sterilization is a broadly used terminal sterilization method for medical devices.
- EO sterilization and irradiation as a terminal sterilization can also cause limitations for medical devices or more specifically wound dressings containing antimicrobial positive and negative dyes. One example is a limitation on materials that can be used as different materials have their properties changed by sterilization. In the case of wound dressings, medical silicone adhesives and silicon rubbers are excluded from use in gamma terminally sterile products, e.g. as cover dressings, despite their excellent clinical performance. Therefore, a wound dressing comprised of an antimicrobial positive and negative dyed wound dressing and a silicone adhesive is not known in the prior art.
- In U.S. Patent Application Publication Number US2013/0032967 published Feb. 7, 2013 describes a method of EO sterilization on polymeric stents where the temperature is kept below 40° C. to limit or eliminate negative impacts on polymeric stents caused by ethylene oxide sterilization.
- Hsiao et al. (Polymer Degradation and Stability, 2012, 97, 715) reported EO sterilization to have a substantial effect on the release pattern of drugs embedded in a biodegradable polymer scaffold. In one case, the total drug-releasing period for the EO-treated samples was much shorter than that of untreated controls, and the overall amount of released antibiotic was less.
- Chrzanowski et al. (Journal of Applied Polymer Science, 2014, 131, 40812) reported that EtO sterilization resulted in destruction of poly (1-lactide-co-glycolide) (PLGA) vascular prostheses, where radiation sterilization did not affect the material.
- Polymeric based wound dressings made from e.g. polyvinyl alcohol (PVA) or polyurethane-polyether (PU) polymers and that contain antimicrobial positive and negative dyes are terminally sterilized using irradiation, e.g. Hydrofera® Blue (Hydrofera, LLC), RTD® Wound Dressing (Keneric Healthcare), NovaGran™ Blue Plus Dressing™ (Principle Business Enterprises, Inc.). In all known cases, the use of medical silicone adhesives is excluded from the device's design.
- None of the aforementioned references attempt to increase the effect of antimicrobial positive and negative dyes or allow the uses of silicone adhesives with sterile product to prevent or preclude biofilm from forming on wounds.
- Wounds often have multiple barriers to healing. Wound healing and infection is influenced by the relationship between the ability of bacteria to create a stable, prosperous community within a wound environment and the ability of the host to control the bacterial community. Since bacteria are rapidly able to form their own protective microenvironment (biofilm) following their attachment to a surface, the ability of the host to control these organisms is likely to decrease as the biofilm community matures. Within a stable biofilm community, interactions between aerobic and anaerobic bacteria are likely to increase their net pathogenic effect, enhancing their potential to cause infection and delay healing. Over the last few years, some have linked biofilm to chronic wounds. Microscopic evaluation or chronic wounds showed well organized biofilm with extracellular polymeric substance adhered around colony bacteria in at least 60% of the chronic wounds.
- There is thus a need for new methods of making dressings and other medical devices with absorbed or impregnated therapeutic agents, more specifically antimicrobial positive and negative dyes, where the medical devices' performance is not impaired by an EO sterilization step. The above noted teachings do not aid in the resolution of a number of practical difficulties that are resolved by the present invention.
- The present invention describes Ethylene Oxide terminally sterilizing sterile dressings with enhanced antimicrobial properties. Enhanced antimicrobial properties are achieved through the method of using gamma irradiation as a processing step on the dyed medical device prior to final assembly and terminal EO sterilization.
- The invention allows for incorporation of non-gamma stable parts, e.g. silicones, in the final assembled product followed by terminal EO sterilization of the finished device. The gamma irradiation process step prior to the terminal EO sterilization surprisingly gives improved antimicrobial properties in comparison to the same device without the prior irradiative step. In a preferred embodiment, the device is an antibacterial dressing. The invention is directed to methods and processes for making these terminal EO sterile antimicrobial positive and negative dyed medical devices.
- It is an object of the invention to make sterilized dressings and medical devices with integrated antimicrobial positive and negative dyes using silicone adhesives.
- It is another object of the invention to make a sterilized antimicrobial positive and negative dye containing sponge dressing whereby the dye effectiveness against micro-organisms is enhanced by the sterilization process.
- It is yet another object of the invention to provide an effective wound dressing comprising antimicrobial polymer for the treatment of chronic wounds that is capable of donating and absorbing moisture and exudate for optimal wound healing.
- The present invention will be described with reference to the appended Figures, in which:
-
FIG. 1 is a schematic block drawing of gamma radiation with subsequent EO sterilization; -
FIG. 2 is a schematic block drawing of gamma radiation with two comparative EO sterilization methods; -
FIG. 3 is a schematic block drawing likeFIG. 2 with EO sterilization before the gamma sterilization step; and -
FIG. 4 is a plan view of the inventive dressing showing the silicone sheet extending beyond the sponge material. - These and other objects, advantages, and novel features of the present invention will become apparent when considered with the teachings contained in the detailed disclosure along with the accompanying drawings.
- Use of the singular herein includes the plural and vice versa unless expressly stated to be otherwise, or obvious from the context that such is not intended. That is, “a” and “the” refer to one or more of whatever the word modifies. For example, “a device” includes one device, two devices, etc. Likewise, “a polymer” may refer to one, two or more polymers, and “the polymer” may mean one polymer or a plurality of polymers. By the same token, words such as, without limitation, “devices” and “polymers” would refer to one device or polymer as well as to a plurality of devices or polymers unless, again, it is expressly stated or obvious from the context that such is not intended.
- In the same manner, any ranges presented are inclusive of the end-points. For example, “a temperature between 10° C. and 30° C.” or “a temperature from 10° C. to 30° C.” includes 10° C. and 30° C., as well as any temperature in between.
- Also, words of approximation when used herein such as, without limitation, “about” “substantially,” “essentially” and “approximately” mean that the word or phrase modified by the term need not be exactly that which is written but may vary from that written description to some extent. The extent to which the description may vary will depend on how great a change can be instituted and have one of ordinary skill in the art recognize the modified version as still having the properties, characteristics and capabilities of the modified word or phrase. In general, but with the preceding discussion in mind, a numerical value herein that is modified by a word of approximation may vary from the stated value by plus or minus 15%, unless expressly stated otherwise.
- The aspects of the present invention are described in the following paragraphs along with their preferred embodiments. In the below text the term “wound” is to be understood in its broadest sense, i.e. as any exterior part of a human or animal body that may be in need of treatment, particularly antibacterial treatment. Examples of wounds in the present context includes but are not limited to: Any laceration to the skin, such as a wound, a chronic wound, a burn wound, a cut, wounds associated with dermatological conditions, grafts, pressure wounds, traumatic wounds, underlying infections with fistulation from bone, joint or soft tissue. The present invention uses polymeric foam or sponges treated with antibacterial or antimicrobial material which is placed over the wound.
- Wound Dressing Materials
- The wound dressing may be a foam or sponge material and may be polymeric in composition where the polymer can be a synthetic substance, a natural substance or combinations thereof. In one example the synthetic polymer can be polyvinyl formal (PVF), polyvinyl acetal, polyurethane, polyester, polyethylene terephthalate or a mixture of polymers. The natural polymer material can be either animal or plant derived, for example, collagen, or chitosan. The preferred sponge material is polyvinyl acetal, polyurethane or polyvinyl formal.
- The foam or sponge has a morphology characterized by an average pore throat diameter of 0.5-500 μm, a fluid retention of 5.5-25.0 mL fluids/g porous material, a density of 0.05-0.15 g polymer/cm3 porous material, and a porosity of 60-99.5%. The cell structure is characterized as open/interconnected with through pores that can be evaluated by techniques such as capillary flow porometry and liquid extrusion porosimetry.
- The silicon adhesive is attached to a
silicone film sheet 30 and is applied to aplanar surface 32 of the sponge material dressing 40. The film sheet may extend beyond the dressing where it can adhere to the skin surface and keep the dressing in place as is shown inFIG. 4 . - While the preferred embodiment of the invention is directed toward treated sponge dressings, it is envisioned as being used on other medical devices such as polyurethane catheters which are highly prone to infection.
- Dyes & Antimicrobial Agents
- The dyes are clinically safe and have antimicrobial properties. The term “antimicrobial” is defined as having the ability to destroy or inhibit the growth of microorganisms, and comprises one or more of the following: antibacterial, antifungal, antiprotozoal, and antiviral. The inventive sterile dressing for treating wounds is made from a polymer sponge containing a plurality of antimicrobial dyes with at least one dye being gram positive and at least one other dye being gram negative. The dressing is exposed to both gamma radiation and ethylene oxide, which increase the sterilibility and allow a silicon adhesive to be secured to said sponge surface.
- Dyes can include, for example, triaryl or diarylmethanes, methylene blue, toluidine blue, methylene violet, azure A, azure B, azure C, brilliant cresol blue, thionin, methylene green, bromcresol green, crystal violet, acridine orange, brilliant green, acridine yellow, quinacrine, trypan blue, trypan red and mixtures of these dyes. In a preferred embodiment, the dyes are methylene blue and crystal violet. The above dye listing contains gram positive and gram negative dyes. Dyes of both charges are utilized to combat a large family of bacteria having gram positive and gram negative characteristics. Other antimicrobials agents can include e.g. chlorhexidine, rifampicin, sparfloxacin and triclosan.
- Radiation Activation after Terminal Sterilization
- In another embodiment, the activation by irradiation occurs after terminal sterilization with EO.
- In the case of devices with parts that are not compatible with the radiation type, masking techniques may be used to shield the non-compatible parts of the sterile device from radiation exposure.
- In another irradiation method for devices with parts that are not compatible with the radiation type, radiation sources with spatial coherence (e.g. lasers) that allows for selectively activating areas of the device that are stable to radiation exposure. These radiation sources may also have high temporal coherence.
- There is currently a need for effective medical products that include active substances which inhibit the growth of and/or kill bacteria, in particular there is a need for wound care products and methods that inhibit the growth of and/or kill biofilm forming bacteria more efficiently.
- Antibacterial Activity Test
- Antibacterial activity is measured in the following manner.
- 1. Prepare duplicate samples of the dyed and processed sponge dressings material in 5×5 cm swatches.
- 2. Prepare duplicate samples in 5×5 cm swatches of the undyed sponge dressings as controls.
- 3. Inoculate each sample (treated and control) with 5.0 mL of approximately 1.0E+06 CFU/mL of each specified challenge organism.
- 4. Challenge organisms are: Staphylococcus aureus (SA, ATCC #6538), Escherichia coli (EC, ATCC #11775), and Pseudomonas aeruginosa (PA, ATCC #9027). These bacteria are three of the five most common bacteria found in wound infections with Staphylococcus aureus (SA, ATCC #6538) being the most common.
- 5. Incubate samples in a humidified atmosphere for 24 hours at 37° C.
- 6. After this initial incubation period express the fluid from each sample, and plate aliquots of serial dilutions to Tryptic-Soy Agar and re-incubate for at least an additional 24 hours at 37° C.
- 7. Following incubation, all plates are removed and the total colony forming units enumerated.
- 8. Assess each treated material versus the original inoculum level.
- PU foam, PVA foam and PVF foam were dyed with methylene blue (MB) and crystal violet (CV), washed with water and dried. The dyed foams or
sponge dressings 10 were then processed throughgamma irradiation 12 andEO 14 steps to obtaintest units 18 in the order shown inFIG. 1 . - Gamma Irradiation
-
- 25-36 kilogray (kGy) dose achieved by controlled exposure to Cobalt 60 and EO Terminal Sterilization
- Pre-Conditioning: N/A
- Cycle Temperature: 108±5° F.
- Cycle Humidity: approximately 30% RH
- Sterilant (EO) Concentration: approximately 600 mg/L
- These EO process conditions represent the absolute minimum achievable set points that can reproducibly achieve a sterility assurance level (SAL) of 10−6 at a production scale.
- After the terminal sterilization step, as shown in
FIG. 1 , the dyed foam material samples were measured for antibacterial properties using the method described in Example 1, with the data being shown in Table 1. The data in Table 1 shows that gamma irradiation as a process step undertaken prior to EO sterilization gave better antibacterial activity than the EO sterilized only test samples. -
TABLE 1 MB CV Average Log Reduction Poly- Load Load Process Terminal (CFU/mL) vs Inoculum mer (mg/g) (mg/g) Gamma EO SA EC PA PVA 0.50 0.80 X 3.76 2.77 1.65 PVA 0.50 0.80 X X 6.18 6.27 6.18 PU 0.08 0.60 X 6.06 1.40 1.98 PU 0.08 0.60 X X 6.18 6.27 6.18 PU1 0.49 0 X −0.39 −1.38 −1.40 PU1 0.49 0 X X 2.44 −0.24 6.16 PU 0.27 0.35 X 2.63 −0.47 1.69 PU 0.27 0.35 X X 3.73 6.20 6.16 PU 0.11 0.60 X 2.04 −0.61 6.14 PU 0.11 0.60 X X 6.21 6.20 6.16 PU 0.00 0.55 X 1.72 −0.64 6.14 PU 0.00 0.55 X X 6.21 6.20 6.16 - The Table 1 notation PU1 in the Polymer column denotes an example using only one dye.
- This data shows surprising results with an increase in antibacterial dye effectiveness for both the PVA and PU sponges which is normally reduced during the EO sterilization step. This allows the use of silicone adhesive on the sponges treated with EO sterilization. As previously noted this Table includes data on polyurethane which includes single dye samples.
- PU foam was dyed with methylene blue (MB) and crystal violet (CV), washed with water and dried. The dyed
foam 10 was then processed usinggamma irradiation 12 per Example 2 followed byEO 14 as described in Example 2 or bystandard EO sterilization 16 conditions to obtaintest samples 18 as listed below. The processing order is outlined inFIG. 2 . - Standard Cycle EO Terminal Sterilization
-
- Dwell Time Limits: 24-48 hours, 50-80% RH, 40-52° C.
- Cycle Temperature Range: 108±5° F.
- Cycle Humidity: <55% RH
- Sterilant (EO) Concentration: approximately 600 mg/L
- After the terminal step, the dyed foams were measured for antibacterial properties using the method described in Example 1. Antibacterial performance for the samples is found in Table 2.
-
TABLE 2 Average Log Reduction MB CV EO EO (CFU/mL) Load Load Method Method vs Inoculum Polymer (mg/g) (mg/g) Example 2 Example 3 SA EC PA PU 0.29 0.35 X 6.27 6.24 6.25 PU 0.29 0.35 X 6.23 −0.78 6.21 PU 0.08 0.60 X 6.27 6.24 6.25 PU 0.08 0.60 X 6.23 0.20 6.21 - PU foam was dyed with methylene blue (MB) and/or crystal violet (CV), washed with water and dried. The dyed foams 10 were then processed as noted in example 2 conditions with the
EO 14 and/or gamma irradiative 12 steps in the order shown inFIG. 3 . - After the final step, the dyed foams were measured for antibacterial properties using the method described in Example 1, and the data is found in Table 3. The data shows that
gamma irradiation 12 as a process step after EO sterilization gave better antibacterial activity than the EU sterilized only samples. -
TABLE 3 MB CV Average Log Reduction Poly- Load Load Terminal Process (CFU/mL) vs Inoculum mer (mg/g) (mg/g) EO Gamma SA EC PA PU 0.08 0.60 X 6.06 1.40 1.98 PU 0.08 0.60 X X 3.00 6.20 6.13 PU 0.49 0 X −0.39 −1.38 −1.40 PU 0.49 0 X X 6.26 4.08 6.13 PU 0.27 0.35 X 2.63 −0.47 1.69 PU 0.27 0.35 X X 6.26 6.26 6.13 PU 0.11 0.60 X 2.04 −0.61 6.14 PU 0.11 0.60 X X 6.26 6.26 6.13 PU 0.00 0.55 X 1.72 −0.64 6.14 PU 0.00 0.55 X X 6.26 6.26 3.92 - Radiation Activation Prior to Dye Addition. White PU foam was processed using gamma radiation at a dose of 25-36 kGy. The foam was then dyed as described in Example 2 or 3 and sterilized by EO as described in Example 2 and 3 and the data found in the tables.
-
TABLE 4 MB CV Average Log Reduction Load Load EO Process (CFU/mL) vs Inoculum Polymer (mg/g) (mg/g) Method Gamma SA EC PA PU 0.29 0.35 Ex2 X X 6.27 6.24 6.25 PU 0.29 0.35 Ex3 X X 6.23 −0.78 6.21 - Thermal Characterization of Radiation Activated Polymers. Radiation activated polymers are characterized by a proportionally larger population of mobile polymer segments vs. their EO only sterilized analogs. Said population of more mobile segments may be distinguished from those without using differential scanning colorimetry, where differences in glass transition temperature (Tg) profiles are measured. In one example, the radiation activated polymers have one or more glass transition endotherms, and the EO only analogs have none detected. In another example, the radiation activated polymers show an increase of greater than 1° C. in the Tg temperature in going from the 1st to 2nd heat cycle vs the EO only analog which shows no change. Without wishing to be bound by theory, a change in the population of mobile polymer segments may translate to a more therapeutically effective antibacterial agent release from the material.
- Dyed foam samples were processed through gamma irradiative and/or EO steps as described in Example 2. When both irradiation and EO steps were conducted, irradiation preceded EO.
- Differential Scanning calorimetry (DSC) was performed using a TA Q2000 Differential Scanning calorimeter in combination with TA Universal Analysis software. At least 2 mg of each sample was placed in hermetically sealed pans for analysis. The samples were each analyzed in duplicate and the average value is reported in Table 5. Polyurethane samples were cooled to −80° C., then heated to 200° C. at 20° C./min, cooled back to −80° C. at 20° C./min. and heated again to 200° C. at 20° C./min. Polyvinyl alcohol samples were heated from 30° C. to 90° C. at 20° C./min, cooled back to 30° C. at 20° C./min and heated again to 90° C. at 20° C./min. Where more than one endotherm was observed, only the major endotherm is reported.
-
TABLE 5 Dyed Step 1 Step 2 Step 3 (° C.) Polymer Sample ID Gamma EO Gamma 1st Heat 2nd Heat 1st to 2nd PVA 042519.4 X 67.011 1.40 3.37 PVA 042519.5 X X 66.88 6.20 2.22 PVA 042519.6 X ND ND ND PVA 062619.1 X X 62.452 56.97 5.48 PU 042519.7 X −30.30 −0.47 8.27 PU 042519.8 X X −31.07 −28.18 2.89 PU 042519.9 X −31.81 −31.81 0 PU 062619.2 X X −29.30 −19.99 9.31 1A second minor endotherm observed on the first heat only at 48.56° C. 2A second minor endotherm observed on the first heat only at 52.44° - Biofilm Reduction Agents
- Biofilm reduction agents are clinically safe and help remove biofilm by breaking up the film structure. Such agents are incorporated onto the sponge prior to the sterilization steps. As an example, enzymes are used to target and break down the extracellular polymer substances of the biofilm and include amylase enzymes (e.g. amyloglucosidase, bacterial amylo novo), protease enzymes (e.g. savinase and everlase) fibrinolytic agents (e.g. plasmin, streptokinase, and nattokinase, and TrypLE), deoxyribonuclease I, glycoside hydrolase dispersin B, and cellulase.
- Also chelating agents are used in the sponge body to sequester the metals that crosslink polysaccharides in the biofilm including ethylenediaminetetraacetic acid (EDTA), citrates, phosphonates and phosphonic acids.
- Surfactants are used to solubilize the biofilm macromolecules, including ionic and non-ionic surfactants. Ionic surfactants may be negatively charged, positively charged, or zwitterionic, and include alkyl sulfates (e.g. sodium dodecyl sulfate), alkyl carboxylates, (e.g. sodium stearate), tertiary or quarternary alkyl ammoniums (e.g. cetrimonium bromide, cetrimonium chloride, cetrimonium stearate), 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). Non-ionic surfactants may include polyethylene glycol, polyethylene oxide, Triton, Tergitol, Pluronics, IGEPELS, Tweens, fatty acid esters.
- The principles, preferred embodiments and modes of operation of the present invention have been described in the foregoing specification. However, the invention should not be construed as limited to the particular embodiments which have been described above. Instead, the embodiments described here should be regarded as illustrative rather than restrictive. Variations and changes may be made by others without departing from the scope of the present invention as defined by the following claims:
Claims (20)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/602,440 US20200129648A1 (en) | 2018-10-24 | 2019-10-07 | Sterilization of Medical Dressings with Enhanced Antimicrobial Properties |
US18/198,469 US20230285197A1 (en) | 2018-10-24 | 2023-05-17 | Sterilization of medical dressings with enhanced antimicrobial properties |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862749902P | 2018-10-24 | 2018-10-24 | |
US16/602,440 US20200129648A1 (en) | 2018-10-24 | 2019-10-07 | Sterilization of Medical Dressings with Enhanced Antimicrobial Properties |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/198,469 Division US20230285197A1 (en) | 2018-10-24 | 2023-05-17 | Sterilization of medical dressings with enhanced antimicrobial properties |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200129648A1 true US20200129648A1 (en) | 2020-04-30 |
Family
ID=70326172
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/602,439 Abandoned US20200129339A1 (en) | 2018-10-24 | 2019-10-07 | Sterilization of medical devices with enhanced antimicrobial properties |
US16/602,440 Abandoned US20200129648A1 (en) | 2018-10-24 | 2019-10-07 | Sterilization of Medical Dressings with Enhanced Antimicrobial Properties |
US16/602,519 Abandoned US20200129340A1 (en) | 2018-10-24 | 2019-10-24 | Wound Dressing containing a vacuum pump |
US18/196,079 Pending US20230310219A1 (en) | 2018-10-24 | 2023-05-11 | Wound dressing containing a vacuum pump |
US18/198,469 Pending US20230285197A1 (en) | 2018-10-24 | 2023-05-17 | Sterilization of medical dressings with enhanced antimicrobial properties |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/602,439 Abandoned US20200129339A1 (en) | 2018-10-24 | 2019-10-07 | Sterilization of medical devices with enhanced antimicrobial properties |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/602,519 Abandoned US20200129340A1 (en) | 2018-10-24 | 2019-10-24 | Wound Dressing containing a vacuum pump |
US18/196,079 Pending US20230310219A1 (en) | 2018-10-24 | 2023-05-11 | Wound dressing containing a vacuum pump |
US18/198,469 Pending US20230285197A1 (en) | 2018-10-24 | 2023-05-17 | Sterilization of medical dressings with enhanced antimicrobial properties |
Country Status (1)
Country | Link |
---|---|
US (5) | US20200129339A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11116884B2 (en) | 2010-12-08 | 2021-09-14 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
US11135315B2 (en) | 2010-11-30 | 2021-10-05 | Convatec Technologies Inc. | Composition for detecting biofilms on viable tissues |
US11241525B2 (en) | 2010-12-08 | 2022-02-08 | Convatec Technologies Inc. | Wound exudate monitor accessory |
US11241339B2 (en) | 2011-11-29 | 2022-02-08 | Convatec Inc. | Perforated binder for laminated wound dressing |
US11266774B2 (en) | 2016-07-08 | 2022-03-08 | Convatec Technologies Inc. | Fluid collection apparatus |
US11286601B2 (en) | 2012-12-20 | 2022-03-29 | Convatec Technologies, Inc. | Processing of chemically modified cellulosic fibres |
US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
US11452808B2 (en) | 2016-07-08 | 2022-09-27 | Convatec Technologies Inc. | Fluid flow sensing |
WO2022201102A1 (en) * | 2021-03-24 | 2022-09-29 | Kerecis Hf | A colored biologic wound treatment providing healing progress monitoring |
US11596554B2 (en) | 2016-07-08 | 2023-03-07 | Convatec Technologies Inc. | Flexible negative pressure system |
US11628093B2 (en) | 2008-05-08 | 2023-04-18 | Convatec Technologies, Inc. | Wound dressing |
US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112998950B (en) * | 2021-03-29 | 2022-05-24 | 李玉艳 | Medical treatment is with filler equipment of dressing sponge ring |
WO2024117756A1 (en) * | 2022-11-30 | 2024-06-06 | (주)시지바이오 | Negative pressure therapy device and method for controlling same |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE505000C2 (en) * | 1996-05-14 | 1997-06-09 | Moelnlycke Ab | Wound dressing and manufacturing process therefore |
US5811471A (en) * | 1997-09-15 | 1998-09-22 | Shanbrom Technologies Llc | Disinfectant plastic sponge material |
US6613347B2 (en) * | 2001-02-21 | 2003-09-02 | Tolland Development Company, Llc | PVA sponge with low durometer skin silicone |
US7358282B2 (en) * | 2003-12-05 | 2008-04-15 | Kimberly-Clark Worldwide, Inc. | Low-density, open-cell, soft, flexible, thermoplastic, absorbent foam and method of making foam |
WO2009114624A2 (en) * | 2008-03-12 | 2009-09-17 | Bluesky Medical Group Inc. | Negative pressure dressing and method of using same |
WO2009151645A2 (en) * | 2008-06-13 | 2009-12-17 | Premco Medical Systems, Inc. | Wound treatment apparatus and method |
JP5671469B2 (en) * | 2008-10-29 | 2015-02-18 | スリーエム イノベイティブ プロパティズ カンパニー | Electron curable silicone release material |
US8944067B2 (en) * | 2010-12-15 | 2015-02-03 | Kci Licensing, Inc. | Targeted delivery of magnetically tagged active agents in combination with negative pressure wound therapy |
WO2014028212A2 (en) * | 2012-08-13 | 2014-02-20 | Kci Licensing, Inc. | Intelligent therapy system with evaporation management |
US20140275864A1 (en) * | 2013-03-15 | 2014-09-18 | Hydrofera, Llc | Polyurethane dressing and method for making same |
EP3288599B1 (en) * | 2015-04-25 | 2023-06-07 | Chemokind, Inc. | Wound packing material comprising chemoeffector |
EP3347068B2 (en) * | 2015-09-11 | 2024-06-12 | Smith & Nephew, Inc | Systems and methods for applying reduced negative pressure therapy |
WO2017075320A1 (en) * | 2015-10-31 | 2017-05-04 | Dermalink Technologies, Inc. | Skin adhesives, antimicrobial compositions, articles, and methods for the use thereof |
EP3522941A4 (en) * | 2016-10-05 | 2020-06-17 | 3M Innovative Properties Company | Fibrinogen composition, method and wound articles |
US11147696B2 (en) * | 2017-01-06 | 2021-10-19 | John James Scanlon | Bioresorbable scaffold having sustained drug delivery |
EP3409248B1 (en) * | 2017-06-01 | 2019-11-06 | Absorbest AB | Wound dressing |
-
2019
- 2019-10-07 US US16/602,439 patent/US20200129339A1/en not_active Abandoned
- 2019-10-07 US US16/602,440 patent/US20200129648A1/en not_active Abandoned
- 2019-10-24 US US16/602,519 patent/US20200129340A1/en not_active Abandoned
-
2023
- 2023-05-11 US US18/196,079 patent/US20230310219A1/en active Pending
- 2023-05-17 US US18/198,469 patent/US20230285197A1/en active Pending
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11628093B2 (en) | 2008-05-08 | 2023-04-18 | Convatec Technologies, Inc. | Wound dressing |
US11135315B2 (en) | 2010-11-30 | 2021-10-05 | Convatec Technologies Inc. | Composition for detecting biofilms on viable tissues |
US11116884B2 (en) | 2010-12-08 | 2021-09-14 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
US11241525B2 (en) | 2010-12-08 | 2022-02-08 | Convatec Technologies Inc. | Wound exudate monitor accessory |
US11241339B2 (en) | 2011-11-29 | 2022-02-08 | Convatec Inc. | Perforated binder for laminated wound dressing |
US11286601B2 (en) | 2012-12-20 | 2022-03-29 | Convatec Technologies, Inc. | Processing of chemically modified cellulosic fibres |
US11266774B2 (en) | 2016-07-08 | 2022-03-08 | Convatec Technologies Inc. | Fluid collection apparatus |
US11452808B2 (en) | 2016-07-08 | 2022-09-27 | Convatec Technologies Inc. | Fluid flow sensing |
US11596554B2 (en) | 2016-07-08 | 2023-03-07 | Convatec Technologies Inc. | Flexible negative pressure system |
US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
WO2022201102A1 (en) * | 2021-03-24 | 2022-09-29 | Kerecis Hf | A colored biologic wound treatment providing healing progress monitoring |
Also Published As
Publication number | Publication date |
---|---|
US20200129339A1 (en) | 2020-04-30 |
US20230310219A1 (en) | 2023-10-05 |
US20200129340A1 (en) | 2020-04-30 |
US20230285197A1 (en) | 2023-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230285197A1 (en) | Sterilization of medical dressings with enhanced antimicrobial properties | |
Galante et al. | Sterilization of hydrogels for biomedical applications: A review | |
JP4481372B2 (en) | Bactericidal plastic sponge material | |
CA2884060C (en) | A prolonged disinfectant composition for non-biological surfaces comprising silver ion water and aloe vera | |
JP2013535996A (en) | Bandage device used with cannula or catheter | |
Poor et al. | Control of multi-drug-resistant pathogens with non-thermal-plasma-treated alginate wound dressing | |
JPH02299662A (en) | Antimicrobial product and composite | |
Rippon et al. | Polyhexamethylene biguanide and its antimicrobial role in wound healing: A narrative review | |
Bento et al. | A review of conventional and emerging technologies for hydrogels sterilization | |
Baume et al. | Sterilization of tissue scaffolds | |
US3876768A (en) | Sterilization of soft, hydrophilic acrylate and methacrylate copolymer materials | |
EP3615144B1 (en) | Method for treatment and prevention of biofilm formation during breast augmentation procedures | |
Wojcik et al. | Biocompatible curdlan-based biomaterials loaded with gentamicin and Zn-doped nano-hydroxyapatite as promising dressing materials for the treatment of infected wounds and prevention of surgical site infections | |
US20230405178A1 (en) | Antimicrobial compression wrap | |
WO2020072089A1 (en) | Sterilization of medical dressings with enhanced antimicrobial properties | |
US20070202006A1 (en) | Disinfecting Solutions Effective Against Bacterial Endospores | |
Shyam et al. | Effect of sterilization techniques on biomaterial inks’ properties and 3D bioprinting parameters | |
Rippon et al. | Effectiveness of a polyhexamethylene biguanide-containing wound cleansing solution using experimental biofilm models | |
Colaço et al. | Sterilization methods | |
Baggini | Sterilization in Microbiology | |
Rosenblatt et al. | Novel in situ liquefying antimicrobial wrap for preventing tissue expander infections following breast reconstructive surgeries | |
CN110917339A (en) | Lysostaphin gel and application thereof in MRSA infected wound surface | |
US20240148932A1 (en) | Wound dressing with preventive biofilm additive | |
Leow-Dyke et al. | The efficacy and sterilisation of human decellularised dermal allografts with combinations of cupric ions and hydrogen peroxide | |
Kumar | Limited access dressing and wound infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
STCC | Information on status: application revival |
Free format text: WITHDRAWN ABANDONMENT, AWAITING EXAMINER ACTION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: HYDROFERA, LLC, CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DRURY, THOMAS J.;HANSON, CHRISTOPHER;O'GARA, JOHN E.;AND OTHERS;REEL/FRAME:059423/0411 Effective date: 20211118 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |